Comparison
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739 vs 17q12 Recurrent Deletion Syndrome C6011081
Clinical comparison between 3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome and 17q12 Recurrent Deletion Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
A severe mitochondrial disorder affecting the brain, hearing, and energy metabolism. It causes progressive neurological decline, hearing loss, and metabolic problems. Management requires intensive supportive care.
17q12 Recurrent Deletion Syndrome C6011081
A genetic condition from deletion on chromosome 17. Can involve developmental delays, neurological features, and potential kidney involvement. Management requires regular monitoring and supportive therapies.
6 comparison axes
Onset
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
0-5
17q12 Recurrent Deletion Syndrome C6011081
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
severe
17q12 Recurrent Deletion Syndrome C6011081
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
Chronic
17q12 Recurrent Deletion Syndrome C6011081
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
No
17q12 Recurrent Deletion Syndrome C6011081
No
Different transmission
Body System
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
metabolic
17q12 Recurrent Deletion Syndrome C6011081
congenital
Same/different system
Category
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
metabolic
17q12 Recurrent Deletion Syndrome C6011081
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-with-deafness-encephalopathy-and-leigh-like-syndrome-C4040739 and 17q12-recurrent-deletion-syndrome-C6011081 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739 | 17q12 Recurrent Deletion Syndrome C6011081 | Discriminating power |
|---|---|---|---|
| Neurologic course | Progressive encephalopathy and Leigh-like neurologic decline may occur. | Developmental delay or neurologic features may occur without a defined progressive metabolic course. | High |
| Hearing | Hearing loss is a named core feature. | Hearing loss is not established as a defining feature from the supplied data. | Moderate |
| Kidney involvement | Kidney disease is not described in the supplied source. | Potential kidney involvement is specifically noted and needs monitoring. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739 when
Infant or young child with progressive neurologic decline and hearing loss
This pattern aligns with the described severe mitochondrial presentation.
Moderate
Suspected energy-metabolism disorder with encephalopathy
Metabolic evaluation is more relevant than chromosomal deletion testing alone.
Moderate
Leigh-like imaging or clinical pattern
The source specifically links this condition to Leigh-like features.
Moderate
Choose 17q12 Recurrent Deletion Syndrome C6011081 when
Developmental delay with possible congenital anomalies
A chromosomal deletion syndrome is a more fitting category.
Moderate
Kidney abnormalities alongside neurodevelopmental concerns
Potential kidney involvement is a supplied distinguishing feature.
Moderate
Family or genomic evaluation suggests a recurrent deletion
Chromosomal microarray or equivalent testing can assess 17q12 deletion.
High
How key tests differ
| Test | 3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739 | 17q12 Recurrent Deletion Syndrome C6011081 | Interpretation |
|---|---|---|---|
| Metabolic urine organic acids | 3-methylglutaconic aciduria may be sought; exact cutoffs are not supplied. | No characteristic organic acid abnormality is established here. | An abnormal result supports further metabolic evaluation but is not itself a diagnosis. |
| Genetic testing | Mitochondrial or related gene testing may be considered by specialists. | Chromosomal microarray can detect a recurrent 17q12 deletion. | Test choice should follow the clinical pattern and genetic counseling. |
| Kidney assessment | No specific kidney abnormality is established by the source. | Monitoring for possible kidney involvement is appropriate. | Normal or abnormal findings need clinician correlation. |
Prognosis comparison
3 Methylglutaconic Aciduria With Deafness Encephalopathy And Leigh Like Syndrome C4040739
- Outcome
- Described as severe, with progressive neurologic decline; exact survival is not established.
- Factors
- Neurologic progression, hearing loss, and metabolic instability may influence needs.
17q12 Recurrent Deletion Syndrome C6011081
- Outcome
- Described as moderate and variable; individual outcome is not established.
- Factors
- Developmental, neurologic, and possible kidney involvement may shape care.
Time frame: Both are chronic; onset may be early, but exact timing is not established.
Prognosis depends on confirmed diagnosis, complications, and supportive care.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic decline | Progressive decline is described and may be severe. Neurologic features can occur, but progression is not established. Severity and course vary; urgent changes need clinical assessment. |
| Hearing impairment | Hearing loss is a named feature. Not established as characteristic from the supplied description. Audiology referral depends on findings rather than diagnosis alone. |
| Renal complications | Not described in the supplied source. Potential kidney involvement warrants surveillance. Exact renal risks and thresholds are not provided. |
Patient education highlights
- HighSpecialist care
Both conditions need individualized specialist follow-up; neither comparison replaces diagnosis or treatment advice.
- HighWarning symptoms
Seek urgent care for breathing difficulty, seizures, reduced responsiveness, or rapid neurologic change.
- MediumMonitoring
Hearing, development, nutrition, and, for 17q12 deletion, kidney health may require scheduled review.